The antiproliferative effects of duligotuzumab or ipatasertib as single agents or in combination with trastuzumab was evaluated in a panel of Her2 positive or negative human gastric cancer cell lines with different biologic profiles. The gene discussed is ERBB2; the disease is gastric cancer.